吉西他滨联合奈达铂治疗晚期非小细胞肺癌的近期疗效观察  

Gemcitabine combined with Nedaplatin in the treatment of advanced non-small cell lung cancer

作　　者：林尤恩[1] 王晓芬[1] 王春冰[1] 许宏伟[1] 邢佳鹏[1] 

机构地区：[1]广东揭阳市人民医院化疗二科,揭阳522000

出　　处：《新医学》2013年第4期250-252,共3页Journal of New Medicine

摘　　要：目的:观察吉西他滨联合奈达铂治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:对确诊为晚期NSCLC的24例患者采用吉西他滨和奈达铂的联合化疗方案,第1日和第8日静脉滴注吉西他滨1 000 mg/m2,30 min内静脉滴注完,化疗第1日静脉滴注奈达铂80mg/m2,21 d为一疗程,共治疗6个疗程。结果:24例患者中部分缓解10例,疾病稳定6例,疾病进展8例,有效率为41.7%(10/24),疾病控制率为66.7%(16/24)。中位疾病进展时间(TTP)为3.2个月,中位生存期为7.9个月。主要的不良反应为骨髓抑制,部分患者有外周神经毒性和恶心、呕吐症状,但症状均较轻。结论:吉西他滨联合奈达铂治疗晚期NSCLC近期疗效较好,患者普遍可以耐受其不良反应。Objective： To observe the efficacy and the side-effects of gemcitabine （GEM） combined with nedaplatin （NDP） on advanced non-small cell lung cancer （NSCLC）. Methods： 24 patients with NSCLC were treated with gemcitabine （GEM 1 000 rag/m2, ivdrip, dl, d8） plus nedaplatin （ NDP 100 rag/m2, ivdrip, dl, every 3 weeks） , each 6 cycles. Results： 10 patients out of 24 were partial response, 6 patients were stable, 8 patients were progressive. The RR was 41.7% （10/24）. Disease control rate was 66.7%. The median time to progress was 3.2 months and the median survivahime was 7.9 months. The main side-effects were fairly, including myelosuppression, partial peripheral neurotoxieity, nausea and vomitin. Conclusion： Gemcitabine combined with nedaplatin is effective and well tolerated in patients with advanced non--small cell lung cancer.

关 键 词：吉西他滨 奈达铂 晚期非小细胞肺癌 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]